CVS Health Corporation $CVS Shares Purchased by Amundi

Key Points

• Amundi increased its CVS Health stake by 2.1% in the second quarter, bringing its holdings to 7.53 million shares worth approximately $778.5 million. Institutional investors collectively own 80.66% of the company.
• Analysts remain broadly positive, with 22 Buy ratings and two Holds producing a consensus “Moderate Buy” rating and an average price target of $106.83.
• CVS reported strong quarterly results, posting adjusted EPS of $2.58 versus the $1.87 estimate and revenue of $106.1 billion, up 7.3% year over year. The company also maintained a quarterly dividend of $0.665 per share, or a 2.7% annualized yield.

Amundi raised its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,525,080 shares of the pharmacy operator's stock after purchasing an additional 154,142 shares during the period. Amundi owned about 0.59% of CVS Health worth $778,469,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new position in CVS Health during the 4th quarter worth $26,000. Kilter Group LLC bought a new stake in CVS Health in the second quarter valued at $27,000. Sankala Group LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $28,000. Finally, Global Trust Asset Management LLC grew its position in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock worth $28,000 after acquiring an additional 300 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CVS. Weiss Ratings upgraded shares of CVS Health from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald upped their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. Mizuho lifted their price target on CVS Health from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Monday, June 8th. Wells Fargo & Company boosted their price objective on CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Finally, TD Cowen increased their price objective on CVS Health from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Monday, May 11th. Twenty-two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $106.83.

CVS Health Price Performance

NYSE CVS opened at $96.80 on Monday. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68. The firm has a market capitalization of $123.80 billion, a PE ratio of 25.61, a P/E/G ratio of 0.94 and a beta of 0.59. The company's 50 day simple moving average is $100.79 and its 200 day simple moving average is $90.22. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same period last year, the company posted $1.81 EPS. The firm's quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts forecast that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's payout ratio is presently 70.37%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source